Abstract
In vitro passage of the Patton strain of herpes simplex virus type 1 (HSV-1-P) in the presence of acycloguanosine (ACG) led to the emergence of a highly drug-resistant strain (HSV-1-P-ACG-R). Over 1% of virions in 6 of 15 HSV strains tested were able to form plaques in the presence of 10 mumol of ACG on first exposure to the drug. Therefore, there exists among HSV strains a broad range of susceptibilities to ACG, and some strains contain particles which are partially resistant to ACG before ever contacting the drug. HSV-1-P-ACG-R was partially resistant to iododeoxyuridine; conversely, iododeoxyuridine-resistant virus was highly resistant to ACG. ACG-resistant virus (HSV-1-P-ACG-R) was equal to its parent strain (HSV-1-P) in susceptibility to adenine arabinoside. The HSV-1-P-ACG-R strain produced corneal lesions in rabbits which were completely refractory to topical treatment with 1% unguent ACG, but responsive to 3% ACG. Partially resistant HSV could be isolated from the eyes of rabbits infected with ACG-susceptible virus and treated topically with either 1 or 3% ACG for 6 days.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Collins P., Bauer D. J. Comparison of activity of herpes virus inhibitors. J Antimicrob Chemother. 1977 Mar;3 (Suppl A):73–81. doi: 10.1093/jac/3.suppl_a.73. [DOI] [PubMed] [Google Scholar]
- Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5716–5720. doi: 10.1073/pnas.74.12.5716. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fyfe J. A., Keller P. M., Furman P. A., Miller R. L., Elion G. B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978 Dec 25;253(24):8721–8727. [PubMed] [Google Scholar]
- Goldman J. M., Chipping P. M., Agnarsdottir G., Brigden D. Acycloguanosine for viral pneumonia. Lancet. 1979 Apr 14;1(8120):820–820. doi: 10.1016/s0140-6736(79)91334-5. [DOI] [PubMed] [Google Scholar]
- JONES B. R., AL-HUSSAINI M. K. THERAPEUTIC CONSIDERATIONS IN OCULAR VACCINIA. Trans Ophthalmol Soc U K. 1963;83:613–631. [PubMed] [Google Scholar]
- Jones B. R., Coster D. J., Fison P. N., Thompson G. M., Cobo L. M., Falcon M. G. Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers. Lancet. 1979 Feb 3;1(8110):243–244. doi: 10.1016/s0140-6736(79)90769-4. [DOI] [PubMed] [Google Scholar]
- Kaplan A. S., Ben-Porat T. Mode of antiviral action of 5-iodouracil deoxyriboside. J Mol Biol. 1966 Aug;19(2):320–332. doi: 10.1016/s0022-2836(66)80007-4. [DOI] [PubMed] [Google Scholar]
- Kaufman H. E., Varnell E. D., Centifanto Y. M., Rheinstrom S. D. Effect of 9-(2-hydroxyethoxymethyl)guanine on herpesvirus-induced keratitis and iritis in rabbits. Antimicrob Agents Chemother. 1978 Dec;14(6):842–845. doi: 10.1128/aac.14.6.842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pavan-Langston D., Buchanan R. Vidarabine therapy of simple and IDU-complicated herpetic keratitis. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976 Sep-Oct;81(5):813–825. [PubMed] [Google Scholar]
- Pavan-Langston D., Campbell R., Lass J. Acyclic antimetabolite therapy of experimental herpes simplex keratitis. Am J Ophthalmol. 1978 Nov;86(5):618–623. doi: 10.1016/0002-9394(78)90178-2. [DOI] [PubMed] [Google Scholar]
- ROIZMAN B., ROANE P. R., Jr A physical difference between two strains of herpes simplex virus apparent on sedimentation in cesium chloride. Virology. 1961 Sep;15:75–79. doi: 10.1016/0042-6822(61)90079-4. [DOI] [PubMed] [Google Scholar]
- SMITH K. O., DUKES C. D. EFFECTS OF 5-IDOO-2-DESOXYURIDINE (IDU) ON HERPESVIRUS SYNTHESIS AND SURVIVAL IN INFECTED CELLS. J Immunol. 1964 Apr;92:550–554. [PubMed] [Google Scholar]